NCT05837338View on ClinicalTrials.gov

Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

July 26, 2023

Study Completion Date

July 26, 2023

Conditions
Wound Bleeding
Interventions
DRUG

BXP154

BXP154 will be self-administered topically following wound induction

DRUG

Placebo

Placebo will be self-administered topically following wound induction

Trial Locations (1)

32720

Accel Research Sites Network - DeLand, DeLand

All Listed Sponsors
lead

Bio 54, LLC

INDUSTRY

NCT05837338 - Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154 | Biotech Hunter | Biotech Hunter